摘要
目的观察分析替加环素与头孢哌酮-舒巴坦联用治疗广泛耐药鲍曼不动杆菌感染的医院获得性肺炎的效果。方法方便选取该院2020年3月—2021年3月收治的60例患者,基于使用药物的差异将其分为观察组30例、对照组30例,均接受头孢哌酮-舒巴坦治疗;观察组额外接受替加环素治疗。对比两组患者治疗成效,治疗前后C反应蛋白(CRP)、白三烯B4(LTB4)、降钙素原(PCT)水平。结果观察组治疗总有效率为93.33%,高于对照组的70.00%,差异有统计学意义(χ^(2)=5.455,P<0.05);治疗前,观察组患者的CRP、LTB4、PCT水平分比为(97.34±14.36)mg/L、(597.36±63.46)ng/L、(2.45±0.56)g/L,与对照组的(96.97±15.27)mg/L、(601.45±58.49)ng/L、(2.53±0.61)g/L相比,差异无统计学意义(t=0.097、0.260、0.529,P=0.923、0.796、0.599);治疗后,观察组3项指标分别为CRP(58.63±10.48)mg/L、LTB4(335.64±37.46)ng/L、PCT(0.85±0.36)g/L,均低于对照组的CRP(74.85±13.46)mg/L、LTB4(458.69±45.40)ng/L、PCT(1.45±0.49)g/L,差异有统计学意义(t=5.208、11.451、5.405,P<0.001)。结论替加环素与头孢哌酮-舒巴坦联用治疗广泛耐药鲍曼不动杆菌感染的医院获得性肺炎时,能有效降低患者CRP、LTB4、PCT水平,治疗成效优于头孢哌酮-舒巴坦单一药物治疗。
Objective To observe and analyze the effect of tigecycline combined with cefoperazone-sulbactam in the treatment of hospital-acquired pneumonia infected by widely drug-resistant Acinetobacter baumannii.Methods Conveniently selected 60 patients admitted to the hospital from March 2020 to March 2021,they were divided into observation group 30 cases and control group 30 cases based on the difference in drug use.All received cefoperazone-sulbactam treatment;the observation group additionally received tigecycline treatment.Compared the treatment effect,the levels of C-reactive protein(CRP),leukotriene B4(LTB4),and procalcitonin(PCT)before and after treatment in the two groups.Results The total effective rate of treatment in the observation group was 93.33%,which was higher than 70.00%in the control group,and the difference was statistically significant(χ^(2)=5.455,P<0.05).Before treatment,the ratios of CRP,LTB4,and PCT levels in the observation group were(97.34±14.36)mg/L,(597.36±63.46)ng/L,and(2.45±0.56)g/L.Compared with the control group(96.97±15.27)mg/L,(601.45±58.49)ng/L,(2.53±0.61)g/L,the difference was not statistically significant(t=0.097,0.260,0.529,P=0.923,0.796,0.599).After treatment,the 3 indicators of the observation group were CRP(58.63±10.48)mg/L,LTB4(335.64±37.46)ng/L,and PCT(0.85±0.36)g/L.They were all lower than those of the control group CRP(74.85±13.46)mg/L,LTB4(458.69±45.40)ng/L,and PCT(1.45±0.49)g/L,the difference was statistically significant(t=5.208,11.451,5.405,P<0.001).Conclusion When tigecycline and cefoperazone-sulbactam are used in the treatment of hospital-acquired pneumonia infected by widely drug-resistant Acinetobacter baumannii,it can effectively reduce the levels of CRP,LTB4,and PCT in patients.The therapeutic effect is better than that of cefoperazone-sulbactam single-drug therapy.
作者
龚原忠
GONG Yuanzhong(Department of Respiratory Medicine,Nanping First Hospital,Nanping,Fujian Province,353000 China)
出处
《中外医疗》
2021年第31期102-104,108,共4页
China & Foreign Medical Treatment
关键词
替加环素
头孢哌酮-舒巴坦
广泛耐药性
鲍曼不动杆菌
医院获得性肺炎
Tegacyclin
Cefoperazone sulbactam
Widespread drug resistance
Acinetobacter baumannii
Hospital acquired pneumonia
